Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
NCT00005850
Completed
This trial is designed to test the efficacy of fluoxetine to improve patient's quality of life during chemotherapy. An innovative application of a selective serotonin reuptake inhibitor may modulate the effects of fatigue, anxiety and depression which worsen quality of life.
Gender:
ALL
Ages:
All
Trial Updated:
07/01/2016
Locations: Northeast Alabama Regional Medical Center, Anniston, Alabama +42 locations
Conditions: Anxiety Disorder, Depression, Fatigue, Lung Cancer
Register for Updates
Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
NCT00006012
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy before, during, and after radiation therapy in treating patients who have limited-stage small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2016
Locations: CCOP - Mayo Clinic Scottsdale Oncology Program, Scottsdale, Arizona +83 locations
Conditions: Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
Register for Updates
Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors
NCT00072215
Terminated
RATIONALE: Drugs used in chemotherapy, such as ifosfamide, cisplatin, paclitaxel, and vinblastine, work in different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether ifosfamide and cisplatin are more effective when combined with paclitaxel or vinblastine in treating germ cell tumors. PURPOSE: This randomized phase III trial is studying paclitaxel, ifosfamide, and cisplatin to see how well they work compared to vinblastine, ifosfamide, and cisplatin... Read More
Gender:
MALE
Ages:
Between 18 years and 120 years
Trial Updated:
07/01/2016
Locations: Northeast Alabama Regional Medical Center, Anniston, Alabama +78 locations
Conditions: Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
Register for Updates
Cisplatin and Irinotecan Followed by Carboplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
NCT00072527
Completed
RATIONALE: Drugs used in chemotherapy, such as cisplatin, irinotecan, carboplatin, and etoposide, use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of cisplatin and irinotecan followed by carboplatin, etoposide, and radiation therapy in treating patients who have limited-stage... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2016
Locations: Beebe Medical Center, Lewes, Delaware +75 locations
Conditions: Lung Cancer
Register for Updates
Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
NCT01151761
Terminated
The purpose of this study is to determine progression-free survival at 12 months for stereotactic body radiotherapy (SBRT) and chemotherapy for unresectable hilar cholangiocarcinoma (CCA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2016
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Cholangiocarcinoma, Hepatobiliary Neoplasm, Liver Cancer, Bile Duct Cancer, Cancer of Gallbladder
Register for Updates
Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors
NCT00984997
Completed
1. To determine the outcome of patients with potentially resectable superior sulcus tumors of non-small cell histology treated by surgery followed by accelerated radiation therapy and chemotherapy. 2. To evaluate toxicity, the initial local-regional control rate, sites of and time to local and distant failures.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/29/2016
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer
Register for Updates
Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00077311
Completed
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as dimesna, may help prevent or decrease the side effects (such as nerve, kidney, and inner ear damage) caused by chemotherapy. PURPOSE: This randomized phase II trial is studying giving docetaxel and cisplatin together with dimesna to see how well it works compared to giving docetaxel and cisplatin alone in tre... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/28/2016
Locations: El Camino Hospital, Mountain View, California +63 locations
Conditions: Anemia, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Neutropenia
Register for Updates
Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma
NCT00705874
Completed
This study will aims to determine the maximum tolerated dose of CGC-11047 when used in individual combinations with gemcitabine, or docetaxel, or bevacizumab, or erlotinib or cisplatin or 5-flurouracil or sunitinib in one of 7 treatment arms. The dose of CGC-11047 will be escalated until the maximum tolerated dose is established.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2016
Locations: Rocky Mountain Cancer Centre, Denver, Colorado +11 locations
Conditions: Cancer
Register for Updates
Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery
NCT01888302
Completed
This pilot phase I trial studies the side effects and best way to give sirolimus, gemcitabine hydrochloride, and cisplatin in treating patients at high risk for cholangiocarcinoma recurrence after liver transplant or surgery. Sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by sto... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2016
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Hepatic Complication
Register for Updates
Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer
NCT00417248
Terminated
Sorafenib has demonstrated in vivo anti-tumor efficacy. This trial will evaluate the safety and preliminary efficacy of sorafenib following chemoradiation in locally advanced NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2016
Locations: Medical & Surgical Specialists, LLC, Galesburg, Illinois +7 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
NCT00686959
Completed
This study will compare the overall survival of participants with locally-advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) with nonsquamous cell histology.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2016
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama +132 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates
A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer
NCT01788566
Completed
The purpose of this study is to see how participants with late stage lung cancer do on gemcitabine-cisplatin chemotherapy plus necitumumab. The study will also see how safe the drugs are in combination and to see how long the medicine stays in the body. The study will last approximately 2 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2016
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama +16 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates